122 related articles for article (PubMed ID: 38478923)
1. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.
Johns AC; Campbell MT; Gao M; Hahn AW; Lim Z; Wang E; Gao J; Shah AY; Msaouel P; Tannir NM
Oncologist; 2024 Mar; ():. PubMed ID: 38478923
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
3. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
4. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Grünwald V; Powles T; Kopyltsov E; Kozlov V; Alonso-Gordoa T; Eto M; Hutson T; Motzer R; Winquist E; Maroto P; Keam B; Procopio G; Wong S; Melichar B; Rolland F; Oya M; Rodriguez-Lopez K; Saito K; McKenzie J; Porta C
Eur Urol Oncol; 2023 Aug; 6(4):437-446. PubMed ID: 36720658
[TBL] [Abstract][Full Text] [Related]
5. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
6. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma.
Hutson TE; Michaelson MD; Kuzel TM; Agarwal N; Molina AM; Hsieh JJ; Vaishampayan UN; Xie R; Bapat U; Ye W; Jain RK; Fishman MN
Eur Urol; 2021 Aug; 80(2):162-170. PubMed ID: 33867192
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Tivozanib Monotherapy as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Multicentric UK Real-World Analysis.
Heseltine J; Allison J; Wong S; Prasad K; Oong ZC; Wong H; Law A; Charnley N; Parikh O; Waddell T; Chow S
Target Oncol; 2023 Jul; 18(4):593-599. PubMed ID: 37285073
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Motzer RJ; Alyasova A; Ye D; Karpenko A; Li H; Alekseev B; Xie L; Kurteva G; Kowalyszyn R; Karyakin O; Neron Y; Cosgriff T; Collins L; Brechenmacher T; Lin C; Morgan L; Yang L
Ann Oncol; 2016 Mar; 27(3):441-8. PubMed ID: 26681676
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
[TBL] [Abstract][Full Text] [Related]
10. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
[TBL] [Abstract][Full Text] [Related]
11. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations.
Ged Y; Gupta R; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Voss MH; Feldman DR; Akin O; Patil S; Motzer RJ; Rini BI; Lee CH
BMC Urol; 2020 Jul; 20(1):84. PubMed ID: 32616076
[TBL] [Abstract][Full Text] [Related]
13. Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Buti S; Olivari A; Masini C; Bimbatti D; Sartori D; Ermacora P; Cattrini C; Vitale MG; Rossi E; Mucciarini C; Rizzo M; Sisani M; Santoni M; Roviello G; Mollica V; Conteduca V; Grillone F; Cinausero M; Prati G; Atzori F; Stellato M; Massari F; Bersanelli M
Ther Adv Urol; 2024; 16():17562872241244574. PubMed ID: 38638242
[TBL] [Abstract][Full Text] [Related]
14. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
Donskov F; Motzer RJ; Voog E; Hovey E; Grüllich C; Nott LM; Cuff K; Gil T; Jensen NV; Chevreau C; Negrier S; Depenbusch R; Bergmann L; Cornelio I; Champsaur A; Escudier B; Pal S; Powles T; Choueiri TK
Eur J Cancer; 2020 Feb; 126():1-10. PubMed ID: 31887537
[TBL] [Abstract][Full Text] [Related]
15. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.
Pal SK; Puente J; Heng DYC; Glen H; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Ciuleanu T; Lee JL; Sunela K; O'Hara K; Binder TA; Peng L; Smith AD; Rha SY
Eur Urol; 2022 Sep; 82(3):283-292. PubMed ID: 35210132
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Pal SK; McGregor B; Suárez C; Tsao CK; Kelly W; Vaishampayan U; Pagliaro L; Maughan BL; Loriot Y; Castellano D; Srinivas S; McKay RR; Dreicer R; Hutson T; Dubey S; Werneke S; Panneerselvam A; Curran D; Scheffold C; Choueiri TK; Agarwal N
J Clin Oncol; 2021 Nov; 39(33):3725-3736. PubMed ID: 34491815
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
18. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
Cerbone L; Nunno VD; Carril Ajuria L; Alves Costa Silva C; Colomba E; Guida A; Salviat F; Hirsch L; Benchimol-Zouari A; Flippot R; Escudier B; Albiges L
Clin Genitourin Cancer; 2022 Feb; 20(1):80-87. PubMed ID: 34688544
[TBL] [Abstract][Full Text] [Related]
19. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
20. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
